Longitudinal Assessment of QT Apex in Tumor-Bearing Dogs Receiving Doxorubicin Monotherapy
Journal of Veterinary Internal Medicine · 2025
DOI: 10.1111/jvim.70169 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Veterinary Internal Medicine, 2025. Verfasst von Keita Kitagawa und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, Florida, USA. Hauptthemen laut MEDLINE: Doxorubicin, Dog Diseases, Antibiotics, Antineoplastic, Neoplasms. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
The cardiac morphologic and functional derangements induced by doxorubicin (DOX) are referred to as DOX-induced cardiotoxicity (DOX-IC). Prolongation of the QT apex (QTa) has been identified as a potential marker for the early detection of DOX-IC in humans.
Objectives
Describe changes in QTa that occur in dogs with cancer undergoing DOX monotherapy. Animals Forty-five client-owned dogs.
Methods
Descriptive analysis of data routinely recorded as part of case management of dogs with cancer. Dogs included in the study had a confirmed malignant neoplasm, received DOX as a monotherapy, and had at least 4 ECGs > 30 s. All ECGs included in the study were recorded before DOX administration. Five heartbeats with a stable signal and minimal artifact were randomly selected from each dog, and the QTa was blindly evaluated in lead II, lead III, or both. Subsequently, a linear mixed model was used to quantify the effect of a cumulative dose of DOX on the QTa interval, adjusting for the effect of the other clinical variables.
Results
Forty-five dogs met the inclusion criteria. Among them, 39/45 received five DOX treatments and 26/45 received six DOX treatments. For ECG analysis, 234 ECGs were evaluated for changes in the QTa. The average cumulative dose of DOX was 154.1 mg/m2. There was no significant impact of the DOX treatments on the change in QTa (p = 0.8).
Conclusions
Administration of DOX up to a cumulative dose of 154.1 mg/m2 does not result in QTa prolongation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, Florida, USA.
- Department of Small Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, Michigan, USA.
- Department of Biostatistics, College of Public Health and Health Professions and College of Medicine, University of Florida, Gainesville, Florida, USA.
- Division of Quantitative Sciences, University of Florida Health Cancer Center, University of Florida, Gainesville, Florida, USA.
ORCID-Profile: Keita Kitagawa, Robert A Sanders, Paulo Vilar Saavedra
Zitieren
APA
Kitagawa, K., Ryave, J., Sanders, R. A., Lee, J. H., Zhang, Z., & Vilar Saavedra, P. (2025). Longitudinal Assessment of QT Apex in Tumor-Bearing Dogs Receiving Doxorubicin Monotherapy. Journal of Veterinary Internal Medicine. https://doi.org/10.1111/jvim.70169
Vancouver
Kitagawa K, Ryave J, Sanders RA, Lee JH, Zhang Z, Vilar Saavedra P. Longitudinal Assessment of QT Apex in Tumor-Bearing Dogs Receiving Doxorubicin Monotherapy. Journal of Veterinary Internal Medicine. 2025. doi:10.1111/jvim.70169
BibTeX
@article{Kitagawa2025,
author = {Kitagawa, Keita and Ryave, Jacob and Sanders, Robert A and Lee, Ji-Hyun and Zhang, Zhongyue and Vilar Saavedra, Paulo},
title = {Longitudinal Assessment of QT Apex in Tumor-Bearing Dogs Receiving Doxorubicin Monotherapy},
journal = {Journal of Veterinary Internal Medicine},
year = {2025},
doi = {10.1111/jvim.70169}
}
EUVIMED